SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — History and Physical — Alan Turing — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.
| Patient | Alan Turing |
|---|
| Date of birth | 1912-06-23 |
|---|
| Identifiers | MRN HR-ML007-SYN-TD; SSN (made up) 000-07-6290 |
|---|
| Document date | 1953-04-14 |
|---|
| Author | Rupert Hallam, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Reason for Visit
New-patient primary care visit for breast enlargement, low libido, and low mood after a year of high-dose estrogen given without his consent [S]
History of Present Illness
This fictional modern episode addresses the presenting concerns below. [S]
- Breasts enlarged and tender after a year of estrogen injections he was made to accept; finds it humiliating and has stopped changing in front of other runners. [S]
- Low mood, poor sleep, low libido, and loss of interest since the prosecution and the hormone course; wants to know whether his body will return to normal, and wants no treatment he has not agreed to. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
- Alan Mathison Turing was born on 23 June 1912 in a nursing home in Paddington, London. [D]
- He was a long-distance runner: he built his strength in cross-country running, was known for running to scientific meetings, and in 1951 was still training for long-distance running on the roads around Wilmslow, where he had bought his first house. [D]
- After reporting a burglary at his home in 1952 he was arrested over a relationship with another man and tried on 31 March 1952 for "gross indecency"; rather than go to prison he accepted, for a year, oestrogen treatment intended to neutralise his libido. [D]
- His biographer Andrew Hodges writes that the drug was probably stilboestrol, a synthetic oestrogen; the 2009 government statement and other sources describe the treatment as a series of injections of female hormones. [D]
- Hodges describes the injurious and humiliating effect of the hormones on his body; it is often repeated that the treatment made him grow breasts, though he is known to have mentioned this only once. [D]
- In a letter of 23 November 1952 he wrote that he had decided to have "another, and rather more co-operative go at a psychiatrist"; this was Jungian analysis with a refugee analyst, and he became very enthusiastic about it and wrote down all his dreams. [D]
- His conviction led to the removal of his security clearance, so that he could no longer work for Government Communications Headquarters as he had since the war. [D]
- After the trial he returned to a wide range of academic work, including morphogenesis, quantum theory, and relativity, at Manchester University. [D]
- The roster lists depression as a primary condition; the sources read document his prosecution, the hormone treatment, and his decision to seek Jungian analysis, but record no diagnosis of depression, so a depressive illness is a retrospective interpretation. [R]
5 later historical claims are omitted because they describe events after the index age. See the teaching note.
Past Medical History
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|
| 31 March 1952 | Year of oestrogen treatment (probably stilboestrol) accepted as the alternative to prison after his conviction for gross indecency | D (CLM-0003, CLM-0004) |
| 1952 | Breast growth attributed to the hormone treatment, which he is known to have mentioned once | D (CLM-0005) |
| November 1952 | Decided to see a psychiatrist again and began Jungian analysis | D (CLM-0006) |
Family History
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
Social History
- Occupation: mathematician and computer scientist; moved here three months ago to a university research post, after a criminal conviction abroad for a consensual relationship with another adult man under a law that criminalizes sex between men [S]
- Sexual orientation: gay; pronouns he/him; lives alone; not in a relationship now; has one or two close friends here and others abroad [S]
- Long-distance runner, usually 40 to 50 km a week; has run less in recent months and stopped changing at the running club because of his chest [S]
- Never smoker; two or three drinks a week; no drug use [S]
- Supports: absorbing research work, running, a few trusted friends, and a willingness to talk to a therapist; no firearms in the home [S]
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Medications
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|
| Cholecalciferol 1,000 units (25 mcg) oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1953-04-14 | active | S |
Review of Systems
Positive for the concerns in the history of present illness. Tall, lean, casually dressed; slightly hesitant speech that becomes quick and precise on technical subjects; wry humor; cooperative. Mood "flattened, and angry about what was done to me"; affect constricted, reactive; thought process linear; no suicidal ideation, intent, or plan; no psychotic features; insight and judgment good. No other systems reported as affected in this synthetic episode. [S]
General Status
Alert and engaged. At intake, working full days but sleeping badly, avoiding the running club changing room, and seeing friends less. [S]
Physical Exam
Vital signs recorded on 1953-04-14; see the Vital Signs section. Mental status: Tall, lean, casually dressed; slightly hesitant speech that becomes quick and precise on technical subjects; wry humor; cooperative; Mood "flattened, and angry about what was done to me"; affect constricted, reactive; thought process linear; no suicidal ideation, intent, or plan; no psychotic features; insight and judgment good. The physical examination is limited to the findings relevant to this synthetic episode. [S]
Structured safety assessment: current ideation absent, intent absent, plan absent, access to means reviewed: yes. Outpatient care with a collaborative safety plan, the 988 Suicide & Crisis Lifeline, and a two-week follow-up. [S]
Vital Signs
| Date | Measure | Value | Unit | Provenance |
| 1953-04-14 | Body height | 178 | cm | S |
| 1953-04-14 | Body weight | 71.4 | kg | S |
| 1953-04-14 | Body mass index (BMI) [Ratio] | 22.5 | kg/m2 | S |
| 1953-04-14 | Systolic blood pressure | 122 | mm[Hg] | S |
| 1953-04-14 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1953-04-14 | Heart rate | 64 | /min | S |
| 1953-04-14 | Respiratory rate | 14 | /min | S |
| 1953-04-14 | Body temperature | 36.6 | Cel | S |
| 1953-04-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
Results
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
| 1953-04-14 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 15 | {score} | | | S |
| 1953-04-14 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 8 | {score} | | | S |
| 1953-04-14 | Total score [AUDIT-C] | 2 | {score} | | | S |
| 1953-04-14 | Testosterone [Mass/volume] in Serum or Plasma | 112 | ng/dL | 264-916 ng/dL | Low | S |
| 1953-04-14 | Estradiol (E2) [Mass/volume] in Serum or Plasma | 148 | pg/mL | 7.6-42.6 pg/mL | High | S |
| 1953-04-14 | Lutropin [Units/volume] in Serum or Plasma | 0.3 | m[IU]/mL | 1.7-8.6 m[IU]/mL | Low | S |
| 1953-04-14 | Follitropin [Units/volume] in Serum or Plasma | 0.4 | m[IU]/mL | 1.5-12.4 m[IU]/mL | Low | S |
| 1953-04-14 | Sex hormone binding globulin [Moles/volume] in Serum or Plasma | 88 | nmol/L | 16.5-55.9 nmol/L | High | S |
| 1953-04-14 | Prolactin [Mass/volume] in Serum or Plasma | 21.6 | ng/mL | 4-15.2 ng/mL | High | S |
| 1953-04-14 | Choriogonadotropin.beta subunit [Units/volume] in Serum or Plasma | 1 | m[IU]/mL | <=3 m[IU]/mL | Normal | S |
| 1953-04-14 | Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma | 2.6 | ng/mL | <=8.3 ng/mL | Normal | S |
| 1953-04-14 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-55 U/L | Normal | S |
| 1953-04-14 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 8-48 U/L | Normal | S |
| 1953-04-14 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1953-04-14 | Creatinine [Mass/volume] in Serum or Plasma | 0.96 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1953-04-14 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1948)/1.73 sq M | 102 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1953-04-14 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.4-4 mIU/L | Normal | S |
| 1953-04-14 | Hemoglobin [Mass/volume] in Blood | 13 | g/dL | 13.2-16.6 g/dL | Low | S |
| 1953-04-14 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 22 | ng/mL | 30-100 ng/mL | Low | S |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Bilateral gynecomastia, tender, about 4 cm of firm glandular tissue behind each nipple, after a year of high-dose estrogen; synthetic modern diagnosis linked to the documented breast growth from his hormone treatment | active | confirmed |
N62 | S — Synthetic modern diagnosis. That the hormone treatment caused breast growth is reported in the sources (D, mentioned once in his own words); the examination findings are synthetic. |
| Suppressed testosterone and gonadotropins from exogenous estrogen (drug-induced hypogonadotropic hypogonadism), with low libido, erectile difficulty, and fatigue | active | confirmed |
E23.1 | S — Synthetic consequence of high-dose estrogen, which suppresses LH and FSH; recovery is expected once it stops. |
| Adverse effects of high-dose estrogen given for a year without free and informed consent, as the alternative to imprisonment | active | confirmed |
T38.5X5A | S — Synthetic modern framing of the documented hormone treatment imposed after his conviction (D); in the modern episode it is recorded as iatrogenic harm. |
| Major depressive disorder, single episode, moderate, after prosecution and coerced hormone treatment; synthetic modern diagnosis (no depression diagnosis is documented in his lifetime) | active | confirmed |
F32.1 | S — Synthetic modern diagnosis. That he sought Jungian analysis after the trial is documented (D); calling his state then a depressive illness is a retrospective interpretation (R). |
| Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL) | active | confirmed |
E55.9 | S — Synthetic finding of the bone-health workup. |
Assessment
- Bilateral gynecomastia, tender, about 4 cm of firm glandular tissue behind each nipple, after a year of high-dose estrogen; synthetic modern diagnosis linked to the documented breast growth from his hormone treatment: active, confirmed [S]
- Suppressed testosterone and gonadotropins from exogenous estrogen (drug-induced hypogonadotropic hypogonadism), with low libido, erectile difficulty, and fatigue: active, confirmed [S]
- Adverse effects of high-dose estrogen given for a year without free and informed consent, as the alternative to imprisonment: active, confirmed [S]
- Major depressive disorder, single episode, moderate, after prosecution and coerced hormone treatment; synthetic modern diagnosis (no depression diagnosis is documented in his lifetime): active, confirmed [S]
- Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL): active, confirmed [S]
Plan of Treatment
- Consent first: every examination, test, and treatment is explained and offered, and he may decline any of it; intimate examinations only with his agreement at each step and with a chaperone offered. The estrogen he was given as a condition of avoiding prison was not freely consented treatment, and no further doses will be given. Guideline: EAA clinical practice guidelines: gynecomastia evaluation and management (2019); Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018); APA Guidelines for Psychological Practice With Sexual Minority Persons (2021) [S]
- Gynecomastia workup: breast and testicular examination; testosterone, estradiol, LH, FSH, prolactin, SHBG, hCG, AFP, liver, kidney, and thyroid tests today; scrotal ultrasound; breast ultrasound only if the examination becomes equivocal. Guideline: EAA clinical practice guidelines: gynecomastia evaluation and management (2019); Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018) [S]
- Endocrinology consultation to confirm that the estrogen explains the findings and to advise on recovery of the gonadal axis, testosterone therapy, bone health, and surgery. Guideline: EAA clinical practice guidelines: gynecomastia evaluation and management (2019); Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018) [S]
- Watchful waiting for the gynecomastia after the estrogen stops; testosterone, estradiol, LH, and FSH every six to eight weeks until normal; no testosterone therapy while the axis is recovering; a surgical opinion if gynecomastia persists about twelve months and troubles him. Guideline: EAA clinical practice guidelines: gynecomastia evaluation and management (2019); Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018) [S]
- Bone health: vitamin D replacement, calcium from food, continued running and strength work; bone density scan only if hypogonadism persists beyond six months or a fracture occurs. Guideline: EAA clinical practice guidelines: gynecomastia evaluation and management (2019); Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018); Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline (2012) [S]
- Weekly psychotherapy with a gay-affirming clinic psychologist for about 16 sessions, addressing the prosecution, the coerced treatment, and minority stress; an antidepressant offered and declined for now, to be reconsidered if the PHQ-9 has not fallen by half at about eight weeks. Guideline: VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); APA Guidelines for Psychological Practice With Sexual Minority Persons (2021) [S]
- Collaborative safety plan with warning signs, coping steps, people to contact, the clinic number, and the 988 Suicide & Crisis Lifeline; suicide-risk review and PHQ-9 at every visit. Guideline: VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026) [S]
- Sexual health as routine adult care: HIV and STI testing and a PrEP discussion offered at his preventive visit, with his consent; libido and erectile function reviewed as testosterone recovers. Guideline: APA Guidelines for Psychological Practice With Sexual Minority Persons (2021); Sexually Transmitted Infections Treatment Guidelines: Men Who Have Sex with Men (2021); Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis (2023) [S]
- Affirming practice: his orientation, name, and pronouns recorded as he chooses; his records shared only with his consent; a written letter from this clinic, at his request, confirming that the estrogen he was given was not medically indicated. Guideline: APA Guidelines for Psychological Practice With Sexual Minority Persons (2021) [S]
- Referral to endocrinology, Celia Montrose-Adeyemi, MD, ordered 1953-04-14 [S]